Title Image

R&D

Quetiapine XR
Quetiapine XR
Indication Schizophrenia
Status ­ ‒ ­ US Launched in November 2016 by Par Pharmaceutical.
­ ‒ ­ Canada Launched by a commercialization partner of Handa.
Product Advantages ­ ‒ ­ First- to File, 180-day market exclusivity right in the USA.
­ ‒ ­ Final approval for 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg.
Market Size Handa has received profit sharing of more than $20 million in the USA and more than $3.5 million in Canada.